Here is a summary of three biopharmaceutical stocks investors should keep on their radar for the remainder of the week, according to Bio Pharma Catalyst.
Continue Reading Below
Of particular note to investors, the data presented here best represents investor expectations and data derived from company presentations and may not necessarily be accurate.
Opexa Therapeutics Inc (OPXA) is a biopharmaceutical company focused on the treatment of various diseases, including multiple sclerosis. The company indicated in a presentation that top-line data from a Phase 2b study involving its tovaxin (Tcelna) could be reported on October 14.
Continue Reading Below
Egalet Corp (EGLT) is a specialty pharmaceutical company that manufacturers and commercializes treatments for pain and other conditions.
A U.S. Food and Drug Administration (FDA) advisory committee voted 18 to 1 to recommend approval for the company's ARYMP ER (morphine sulfate) for the treatment of pain severe enough to require daily long-term opiod treatment.
The FDA is not bound by the recommendation of the advisory committee but will consider their guidance during a review. The FDA Prescription Drug User Fee Act (PDFUA) goal date for a decision is scheduled for October 14.
Windtree Therapeutics Inc (WINT) is a biotechnology company focused on developing therapies for respiratory diseases and other potential applications.
The company said in an SEC regulatory filing that enrollment in an AEROSURF phase 2a clinical study involving 32 premature infants receiving the company's proprietary KL4 surfactant with its novel aerosol delivery system.
Enrollment was expected to be completed in September 2016, and top-line results were said to be released "in late September or early October 2016."
At Last Check ...
- iShares NASDAQ Biotechnology Index (ETF) (IBB) was down 0.14 percent at $269.76.
- Egalet was down 1.21 percent at $7.32.
- Opexa was down 5.15 percent at $3.68.
- Windtree was down 1.66 percent at $2.66.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email email@example.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.